ADAMAS PHARMACEUTICALS INC's ticker is ADMS and the CUSIP is 00548A106. A total of 100 filers reported holding ADAMAS PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is 0.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2019 | $52,000 | -18.8% | 10,090 | -2.9% | 0.00% | – |
Q2 2019 | $64,000 | -22.9% | 10,392 | -11.2% | 0.00% | – |
Q1 2019 | $83,000 | -16.2% | 11,704 | +0.8% | 0.00% | -100.0% |
Q4 2018 | $99,000 | -64.1% | 11,611 | -15.7% | 0.00% | -50.0% |
Q3 2018 | $276,000 | -25.0% | 13,777 | -3.2% | 0.00% | 0.0% |
Q2 2018 | $368,000 | +5.4% | 14,235 | -2.4% | 0.00% | 0.0% |
Q1 2018 | $349,000 | -28.9% | 14,591 | +0.7% | 0.00% | -33.3% |
Q4 2017 | $491,000 | +69.3% | 14,490 | +5.9% | 0.00% | 0.0% |
Q3 2017 | $290,000 | +30.0% | 13,689 | +7.2% | 0.00% | +50.0% |
Q2 2017 | $223,000 | -7.5% | 12,771 | -7.3% | 0.00% | -33.3% |
Q1 2017 | $241,000 | -17.2% | 13,781 | -19.9% | 0.00% | 0.0% |
Q4 2016 | $291,000 | +14.6% | 17,205 | +11.2% | 0.00% | -25.0% |
Q3 2016 | $254,000 | -7.6% | 15,466 | -14.7% | 0.00% | 0.0% |
Q2 2016 | $275,000 | +9.6% | 18,138 | +4.6% | 0.00% | +33.3% |
Q1 2016 | $251,000 | -45.7% | 17,344 | +6.2% | 0.00% | -50.0% |
Q4 2015 | $462,000 | – | 16,327 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
GREAT POINT PARTNERS LLC | 2,601,351 | $43,963,000 | 9.03% |
Granite Point Capital Management, L.P. | 256,031 | $4,327,000 | 3.45% |
Opaleye Management Inc. | 285,000 | $4,817,000 | 2.84% |
Brenner West Capital Advisors | 1,221,463 | $20,643,000 | 2.28% |
ARMISTICE CAPITAL, LLC | 536,000 | $9,058,000 | 2.14% |
NEXTHERA CAPITAL LP | 151,670 | $2,563,000 | 1.50% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 185,234 | $3,130,000 | 1.41% |
Cheyne Capital Management (UK) LLP | 144,765 | $2,448,000 | 1.38% |
SPHERA FUNDS MANAGEMENT LTD. | 270,000 | $4,563,000 | 1.16% |
Mosaic Family Wealth, LLC | 123,314 | $2,084,000 | 0.96% |